Cost-effective diabetes medications
Pro Research Analysisby 
Searched over 200M research papers
Cost-Effective Diabetes Medications: Overview of Newer Antidiabetic Drugs
Recent research has focused on the cost-effectiveness of newer antidiabetic medications, especially as second-line treatments for type 2 diabetes. The main drug classes evaluated include sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and dipeptidyl peptidase 4 inhibitors (DPP-4i) Zhu2023Schousboe2024Laursen2023+1 MORE.
SGLT2 Inhibitors and GLP-1 Receptor Agonists: Comparative Cost-Effectiveness
Multiple studies consistently show that SGLT2 inhibitors are more cost-effective than GLP-1 receptor agonists for patients whose diabetes is not controlled by metformin alone Zhu2023Laursen2023. SGLT2 inhibitors also tend to be more cost-effective than DPP-4 inhibitors and sulfonylureas in several analyses Zhu2023Laursen2023. GLP-1 receptor agonists are generally cost-effective compared to DPP-4 inhibitors, sulfonylureas, and insulin, except in a few cases where sulfonylureas were found to be more economical Zhu2023Laursen2023Hong2019.
DPP-4 Inhibitors and Traditional Medications
DPP-4 inhibitors are often more cost-effective than older, traditional antidiabetic drugs, such as sulfonylureas and thiazolidinediones, but less so compared to SGLT2 inhibitors and GLP-1 receptor agonists Zhu2023Laursen2023Hong2019. However, the overall cost-effectiveness of DPP-4 inhibitors can vary depending on the specific patient population and healthcare setting .
First-Line vs. Second-Line Therapy: Value Considerations
As first-line therapy, both GLP-1 receptor agonists and SGLT2 inhibitors are considered low value due to their higher costs compared to metformin . However, when added to metformin or other background therapy as second-line agents, they may offer intermediate value, especially when compared to adding no additional therapy . The value of these newer drugs is highly sensitive to their effectiveness and price .
Cost-Effectiveness of Insulin Formulations
For type 1 diabetes, long-acting and ultralong-acting insulins are generally more cost-effective than intermediate-acting insulins, with ultralong-acting insulins often being the most cost-effective option . In type 2 diabetes, newer once-weekly basal insulins like insulin icodec are cost-effective compared to daily basal insulin analogues, especially at standard pricing levels .
Digital Therapeutics and Non-Pharmacologic Options
Prescription digital therapeutics, such as BT-001, have shown to be cost-effective when added to standard care, leading to both cost savings and improved quality-adjusted life years (QALYs) by reducing drug acquisition costs and diabetes complications . However, for diabetes prevention, lifestyle modification remains more cost-effective than metformin, with metformin not showing cost-effectiveness compared to lifestyle changes in prevention settings .
Newer Agents: Tirzepatide and Semaglutide
Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides greater reductions in HbA1c and weight compared to semaglutide, but at a higher cost. Its cost-effectiveness depends on the willingness-to-pay threshold for each unit of clinical improvement . Some studies also find that oral and injectable semaglutide, as well as empagliflozin, are cost-effective compared to other within-class products, though results can be conflicting .
Conclusion
Overall, SGLT2 inhibitors and GLP-1 receptor agonists are generally cost-effective as second-line therapies for type 2 diabetes, especially when compared to older drugs like sulfonylureas and insulin Zhu2023Schousboe2024Laursen2023+1 MORE. SGLT2 inhibitors often provide the best value among newer agents. The cost-effectiveness of any diabetes medication depends on drug price, patient characteristics, and healthcare system context. Digital therapeutics and lifestyle interventions can also offer significant value, particularly in prevention and long-term management Davison2024Rittenhouse2023.
Sources and full results
Most relevant research papers on this topic
Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
Newer antidiabetic drugs, especially SGLT2i, are cost-effective as second-line treatments for type 2 diabetes, with GLP-1RA being the most cost-effective option.
Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis
Strategy 7 is the most cost-effective strategy for type 2 diabetes treatment, providing higher QALYs but lower costs compared to other strategies.
The Cost-Effectiveness Of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.
Long-acting insulin may be cost-effective compared to intermediate-acting insulin for type 1 diabetes patients, with ultralong-acting insulin being the most cost-effective option.
DOI